Top

Published in:

01-01-2008 | Letters to the Editor

Peritoneal Recurrence for Gastric Cancer: Can It Be Prevented?

Author: Theodore Liakakos, Associate Professor of Surgery

Published in: Annals of Surgical Oncology | Issue 1/2008

Excerpt

Metastatic recurrence after complete surgical resection (R0) is the main cause of death for patients with solid cancers. The particular problem with gastric cancer is that beyond systemic dissemination of cancer cells through blood circulation, cells escape from primary tumor and form secondary tumors also at peritoneal surface (carcinomatosis). It is unknown whether adjuvant systemic chemotherapy is effective in reducing peritoneal recurrence.1 …

Roukos DH, Kappas AM. Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol 2005; 2:98–107PubMedCrossRef

Moon YW, Jeung HC, Rha SY, et al. Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: A 15-year follow-up study at a single Korean institute. Ann Surg Oncol 2007 Jul 14; [Epub ahead of print]

Kappas AM, Fatouros M, Roukos DH. Is it time to change surgical strategy for gastric cancer in the United States? Ann Surg Oncol 2004; 11(8):727–30PubMedCrossRef

Roukos DH, Kappas AM. Targeting the optimal extent of lymph node dissection for gastric cancer. J Surg Oncol 2002; 81(2):59–62PubMedCrossRef

Siewert JR, Bottcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 1998; 228(4):449–61PubMedCrossRef

Roukos DH. Extended (D2) lymph node dissection for gastric cancer: do patients benefit? Ann Surg Oncol 2000; 7(4):253–5PubMedCrossRef

Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345:725–30PubMedCrossRef

Roukos DH. Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol 2002; 9(3):220–1PubMed

Friedman A, Perrimon N. Genetic screening for signal transduction in the era of network biology. Cell 2007; 128(2):225–31PubMedCrossRef

10.

Roukos DH, Murray S, Briasoulis E. Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther 2007; 6(3):308–12PubMedCrossRef

11.

Roukos DH, Kappas AM, Tsianos E. Role of surgery in the prophylaxis of hereditary cancer syndromes. Ann Surg Oncol 2002; 9(7):607–9PubMedCrossRef

Title: Peritoneal Recurrence for Gastric Cancer: Can It Be Prevented?
Author: Theodore Liakakos, Associate Professor of Surgery
Publication date: 01-01-2008
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 1/2008
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-007-9586-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Peritoneal Recurrence for Gastric Cancer: Can It Be Prevented?

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2008

Should Pelvic and Para-aortic Lymphadenectomy Be Different Depending on Histological Subtype in Epithelial Ovarian Cancer?

Lymphadenectomy in Surgical Oncology

‘Telangiectatic’ Transformation in Soft Tissue Sarcomas. A Clinicopathology Analysis of an Aggressive Feature of High-grade Sarcomas

Status of Sentinel Lymph Node Biopsy in Gynecological Cancers

Radiofrequency Ablation Versus Resection for Resectable Colorectal Liver Metastases: Time for a Randomized Trial?

Radiofrequency Ablation for Metachronous Liver Metastasis from Colorectal Cancer after Curative Surgery